These granulocytes with CR3-bound β-glucan-fluorescein when enrolled to a site of complement activation were enabled CR3 to trigger cytotoxicity of inactivated complement 3b (iC3b)-opsonized tumor cells, covered in monoclonal antibodies (mAb) (148). Here, CRIPTO3 is linked to neoplasm.